<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343732</url>
  </required_header>
  <id_info>
    <org_study_id>OCD-DTMS-1</org_study_id>
    <nct_id>NCT01343732</nct_id>
  </id_info>
  <brief_title>Tolerability, Safety and Efficacy of the HAC-Coil Deep Transcranial Magnetic Stimulation in Medication Resistance Obsessive Compulsive Disorder (OCD) Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainsway</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether the combination of deep transcranial magnetic
      stimulation (DTMS) treatment with customary medication for obsessive compulsive disorder
      (OCD) patients is effective than treatment that include only medication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Y-BOCS Scale (Yale-Brown Obsessive Compulsive Disorder)</measure>
    <time_frame>the primary outcome will be measure at day, 8, 22, 31, and 33</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>healthy volunteeres</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>this arm will undergo only EEG measurement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>real - low frequency</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this arm will receive DTMS treatment with low frequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>real - high frequency</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this arm will receive DTMS treatment with high frequency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham - low / high frequency</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>this arm will receive DTMS sham treatment with low or high frequency</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep TMS</intervention_name>
    <description>deep transcranial magnetic stimulation</description>
    <arm_group_label>real - low frequency</arm_group_label>
    <arm_group_label>real - high frequency</arm_group_label>
    <arm_group_label>sham - low / high frequency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients

          2. Men and Women 18-65 years of age.

          3. Diagnosed as suffering from OCD according to DSM-IV.

          4. Patients having OCD of at least moderate severity (YBOCS score of 20 or above).

          5. Patients are maintained on an medication at steady dosages for at least 8 weeks before
             study entry and for the duration of the trail.

          6. Negative answers on safety screening questionnaire for transcranial magnetic
             stimulation.

          7. According to the treating physician the patients is compliant with taking medication.

          8. Capable and willing to provide informed consent.

          9. Able to adhere to treatment schedule.

         10. Patients that participate in behavioral therapy, will be in the maintaining stage and
             not in the active or intensive stage.

        Exclusion Criteria:

          1. Any other Axis I diagnosis as the primary diagnosis.

          2. History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT) or
             history of such in first degree relatives).

          3. OCD patients that have only symptoms of hoarders)

          4. patients with Suicidal tendencies, or the patients is diagnosed as having a Suicidal
             tendencies by the treating physician.

          5. Increased risk of seizure for any reason, including prior diagnosis of increased
             intracranial pressure, or history of significant head trauma with loss of
             consciousness for greater than or equal to 5 minutes.

          6. History of head injury necessitating cranial surgery or prolonged coma.

          7. History of any metal in the head including the eyes and ears (outside the mouth).

          8. Known history of any metallic particles in the eye, implanted cardiac pacemaker or any
             intracardiac lines, implanted neurostimulators, intracranial implant (e.g., aneurysm
             clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical
             pumps.

          9. History of frequent or severe headaches.

         10. History of migraine.

         11. History of significant hearing loss.

         12. Individuals with a significant neurological disorder or insult including, but not
             limited to:

             Any condition likely to be associated with increased intracranial pressure Space
             occupying brain lesion History of cerebrovascular accident Transient ischemic attack
             within two years Cerebral aneurysm Dementia Parkinson's disease Huntington's chorea
             Multiple sclerosis

         13. History of substance abuse including alcoholism within the past 6 months (except
             nicotine and caffeine).

         14. Inadequate communication with the patient.

         15. Participation currently in another clinical study or enrolled in another clinical
             study within 30 days prior to this study.

         16. Participants who suffer from an unstable physical, systemic and metabolic disorders
             such as instabilized blood pressure or acute, unstable cardiac disease.

         17. Women who are breast-feeding.

         18. Known or suspected pregnancy.

         19. Women of childbearing potential and not using a medically accepted form of
             contraception when engaging in sexual intercourse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yossef Zohar, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center, ramat-gan, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yossef Zohar, Prof.</last_name>
    <phone>9723-5303300</phone>
    <email>joseph.zohar@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yossef Zohar, Prof.</last_name>
      <phone>9723-5303300</phone>
      <email>joseph.zohar@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Yossef Zohar, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

